hsa-miR-26b

ncRNA information

ncRNA name

hsa-miR-26b

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

No

Biomarker application

Upstream regulatory factors

Not available

Downstream target

TAZ

Cancer information

Cancer name

Non-Small Cell Lung Cancer

Cancer site

Lung

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Down

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting TAZ.

Tissue resource

human non-small cell lung cancer cell lines PC9

human non-small cell lung cancer cell lines A549

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

the China Center for Type Culture Collection

Country

China

Continent

Asia